Since preferential hyperacuity perimetry (PHP) was first studied as a means of monitoring age-related macular degeneration (AMD) patients in the clinic, the evolution of the technology has been quite dramatic. Today, retina specialists can prescribe the ForeseeHome AMD Monitoring Program (Notal Vision) for patients who are at risk of progressing from dry to neovascular disease. In this program, patients use a PHP self-testing device in their own homes to monitor their vision. PHP detects pattern defects across 500 points in the central 14° of the retina (Figure 1). The test takes approximately 3 minutes per eye, and results from each test session are automatically sent to the Notal Vision monitoring center. The prescribing physician receives monthly reports and can view results online at any time. When test results indicate a statistically significant change in vision, an alert is sent to the prescribing physician so the patient can be promptly seen. More than 2 million PHP tests have been performed using the ForeseeHome device.

Figure 1. More than 2 million preferential hyperacuity perimetry tests have been performed with the ForeseeHome device.

ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia in patients with AMD as an aid in monitoring the progression of disease factors causing metamorphopsia including, but not limited to, choroidal neovascularization. It is intended to be used at home by patients with stable fixation in addition to regularly scheduled eye exams. Diagnosis is the responsibility of the prescribing eyecare professional.

The following articles provide additional information about the ForeseeHome AMD Monitoring Program, which is expected to have a major impact on public health.